Exploring the Untargeted Cysteinome of Protein Kinases

webinar

Thu, 09 Dec 2021, 16:30 CET (Berlin)

Prof. Dr. Matthias Gehringer, University of Tübingen, Germany

Exploring the Untargeted Cysteinome of Protein Kinases

Protein kinases are now among the major drug targets with over 65 inhibitors approved since the groundbreaking approval of imatinib (Gleevec) in 2001. Covalent targeting approaches, which have gained traction in recent years, have proven particularly useful in the protein kinase field. Typically, covalent inhibitors feature superior potency and efficacy as well as a prolonged duration of action. Of the >500 human protein kinases, the so-called “kinome”, almost half are characterized by the presence of an accessible, non-conserved cysteine residue in or around the ATP binding site. Addressing such cysteines by mild electrophiles termed covalent “warheads” enables the rational design of highly potent and selective protein kinase inhibitors as chemical probes or drugs. So far, however, only a small fraction of the protein kinases’ “cysteinome” has been addressed. In this talk, Matthias will present recent efforts toward the development of covalent inhibitors for protein kinases with a cysteine in the so-called “hinge region” using canonical and non-canonical warhead chemistry. Specifically, he will focus on inhibitors targeting TTK/MPS1, a kinase controlling the spindle assembly checkpoint, and S6K2/p70S6Kβ, a neglected member of the ribosomal protein S6 kinase family.

Current news

category
Software
Double Release — SeeSAR 11.1 and infiniSee 3.2
October 14, 2021 12:19
The BioSolveIT October updates are here and this time we are proud to announce a simultanious double release of both our platforms SeeSAR and infiniSee. SeeSAR 11.1 SeeSAR Hephaestus received a powerful update to support users in their drug discovery efforts. The covalent complex assessment received a visual update where...
Read on
category
Software
Asinex Covalent Library with over 50k molecules now available for SeeSAR
September 20, 2021 19:21
Today’s update for the drug design dashboard SeeSAR features the ready-to-dock covalent library set by Asinex including over 50k possible drug candidates. Warheads of compounds have been translated into a ready-to-dock format for SeeSAR for convenient import and easy covalent docking access. The broad range of featured warheads allows you...
Read on
category
Challenge
Winner of Scientific Challenge Fall 2020: FtsZ Inhibitors
September 20, 2021 17:16
We congratulate Benjamin Strickland from the Drew University to winning the Scientific Challenge Fall 2020! In his project he aims to discover novel antibacterial scaffolds and leads for the bacterial cellular division protein filamenting temperature-sensitive mutant Z (FtsZ). The synergistic combination of SeeSAR and infiniSee during his evolutionary virtual high throughput screening...
Read on